<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Alcohol-induced cardiomyopathy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Alcohol-induced cardiomyopathy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Alcohol-induced cardiomyopathy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ihsan M Rafie, MRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wilson S Colucci, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William J McKenna, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 24, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term excess alcohol consumption is a leading cause of secondary dilated cardiomyopathy  (
         <a class="graphic graphic_table graphicRef74268" href="/z/d/graphic/74268.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. However, recovery of cardiac function can occur if the disease is diagnosed early and further alcohol intake is reduced or halted. (See
         <a class="medical medical_review" href="/z/d/html/3516.html" rel="external">
          "Causes of dilated cardiomyopathy"
         </a>
         .)
        </p>
        <p>
         This topic will discuss the pathogenesis, diagnosis, and treatment of alcohol-induced cardiomyopathy. The general and cardiovascular risks and benefits of alcohol consumption are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2781.html" rel="external">
          "Overview of the risks and benefits of alcohol consumption"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2784.html" rel="external">
          "Cardiovascular benefits and risks of moderate alcohol consumption"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24111241">
         <span class="h1">
          DEFINITION AND PREVALENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alcohol-induced cardiomyopathy is a type of acquired dilated cardiomyopathy caused by long-term heavy alcohol consumption. Diagnostic criteria are discussed below. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         below.)
        </p>
        <p>
         The reported prevalence of alcohol-induced cardiomyopathy among patients with heart failure (HF) or dilated cardiomyopathy has varied widely (eg, from 4 to 40 percent or more) and depends on the characteristics of the study population and the threshold alcohol consumption used to identify alcohol-induced cardiomyopathy [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The prevalence of alcohol-induced cardiomyopathy appears to be similar among males and females with alcohol use disorder; however, there is a higher disease burden in males, with a series recording the sex ratio of hospital admission with the condition at almost 9:1 [
         <a href="#rid4">
          4
         </a>
         ]. The main age group affected is from 45 to 59 years old, followed by 60 to 74 years old. Females develop the condition at a lower total dose of ethanol [
         <a href="#rid5">
          5,6
         </a>
         ]. In one series of 50 asymptomatic females with alcohol use disorder and 100 asymptomatic males with alcohol use disorder, approximately one-third of each group had evidence of left ventricle (LV) dysfunction [
         <a href="#rid5">
          5
         </a>
         ]. LV systolic dysfunction correlated with the total lifetime dose of ethanol [
         <a href="#rid5">
          5
         </a>
         ]. However, when patients were matched for LV ejection fraction (LVEF), females consumed a lower total dose of ethanol adjusted for body weight compared with males. Thus, females appear to have increased sensitivity to cardiac toxicity; a similar predisposition has been identified for alcohol-induced liver disease and myopathy. A proposed mechanism for this sex difference is excess accumulation of ethanol metabolites in females due to lower gastric metabolism of ethanol and higher rates of ethanol metabolism in the liver [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3613.html" rel="external">
          "Pathogenesis of alcohol-associated liver disease", section on 'Gastric metabolism of alcohol'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24111678">
         <span class="h2">
          Relation to alcohol consumption
         </span>
         <span class="headingEndMark">
          —
         </span>
         At higher levels of alcohol intake, LV dysfunction and alcohol-induced cardiomyopathy are related to both the mean daily alcohol intake and the duration of drinking [
         <a href="#rid8">
          8-11
         </a>
         ]. Alcohol intoxication can produce acute asymptomatic cardiac dysfunction even when ingested by healthy individuals in quantities typical of social drinking [
         <a href="#rid12">
          12
         </a>
         ]. Likewise, in non-alcohol-dependent subjects, habitual binge-drinking is associated with transient myocardial changes detectable by magnetic resonance imaging (MRI), elevated serum markers for myocardial injury, changes in microindices of myocardial dysfunction, and coronary vasoconstriction [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Most patients in whom alcohol-induced cardiomyopathy develops have been drinking more than 80 to 90 g of ethanol per day for more than five years (some studies quoted an average of 15 years) [
         <a href="#rid1">
          1,8-10,14,15
         </a>
         ]. This corresponds to approximately one liter of wine, eight standard sized beers, or one-half pint of hard liquor each day. The risk is based upon the absolute amount of ethanol, so consumption of a specific type of beverage (such as wine) is not protective.
        </p>
        <p>
         The U-shaped relationship between alcohol intake and HF is similar to that observed for alcohol consumption and survival  (
         <a class="graphic graphic_figure graphicRef82332" href="/z/d/graphic/82332.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2781.html" rel="external">
          "Overview of the risks and benefits of alcohol consumption"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2784.html" rel="external">
          "Cardiovascular benefits and risks of moderate alcohol consumption"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3291143052">
         <span class="h2">
          Relation to liver cirrhosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is evidence of a rough correlation between LV dysfunction and cirrhosis. In one series, cirrhosis was found in 43 percent of 30 persons with alcohol use disorder with cardiomyopathy compared with only 6 percent of 30 persons with alcohol use disorder without cardiomyopathy [
         <a href="#rid16">
          16
         </a>
         ]. Fifty percent of 20 persons with alcohol use disorder with cirrhosis had evidence of dilated cardiomyopathy. Cardiac function was normal in a control group of patients with cirrhosis but without alcohol use disorder.
        </p>
        <p>
         Of note, other studies have identified the separate condition of cirrhotic cardiomyopathy in patients with cirrhosis related to alcohol use disorder or cirrhosis not related to alcohol use disorder. (See
         <a class="local">
          'Cirrhotic cardiomyopathy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of alcohol-induced cardiomyopathy is not fully understood. The toxic effect of acute alcohol binge on cardiac performance is transient, but chronic consumption may result in permanent impairment of myocardial contractility due to the effects of ethanol and its metabolites. The best-known toxic metabolite is acetaldehyde, a metabolite of alcohol produced in the liver by alcohol dehydrogenase. Acetaldehyde is thought to cause myocardial depression through an incompletely understood process that probably involves mitochondrial dysfunction, oxidative damage, and impaired calcium ion homeostasis [
         <a href="#rid17">
          17-23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3613.html" rel="external">
          "Pathogenesis of alcohol-associated liver disease", section on 'Alcohol metabolism'
         </a>
         .)
        </p>
        <p>
         There are several proposed mechanisms by which ethanol consumption may directly or indirectly (via metabolites) cause myocardial damage and cardiomyopathy [
         <a href="#rid24">
          24-28
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ethanol exposure may cause oxidative stress within the myocardium either directly by stimulating the generation of free radicals or indirectly by activating other systems, such as the renin-angiotensin system (RAS) [
         <a href="#rid19">
          19,26,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acetaldehyde from ethanol activates local RAS, which has been implicated in apoptosis leading to myocyte loss and adverse remodeling at the cellular level and arterial hypertension at the systemic level [
         <a href="#rid28">
          28-30
         </a>
         ]. Arterial hypertension may contribute to or worsen HF. (See
         <a class="medical medical_review" href="/z/d/html/2784.html" rel="external">
          "Cardiovascular benefits and risks of moderate alcohol consumption", section on 'Hypertension'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Impaired mitochondrial bioenergetics may contribute, as suggested by studies showing changes in mitochondrial ultrastructure and/or function [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low levels of STAT3 (signal transducer and activator of transcription 3), act as a downstream target for ALDH2 (aldehyde dehydrogenase). ALDH2 provides cardioprotective effects following ethanol exposure via STAT3, which is an important pathway component for mitochondrial respiration [
         <a href="#rid31">
          31
         </a>
         ]. In mice, a moderate alcohol dose stimulates ALDH2, whereas a high dose inhibits ALDH2 [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Altered fatty acid metabolism and transport may contribute to myocardial dysfunction [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Long-term ethanol administration decreases myocardial protein synthesis and accelerates protein catabolism and autophagy [
         <a href="#rid17">
          17,26,29
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Genetic factors may predispose to alcohol-induced cardiomyopathy, though evidence is limited. As an example, DD polymorphism of the angiotensin-converting enzyme (ACE) gene may predispose to alcohol-induced cardiomyopathy. In a study in which 30 males with alcohol use disorder with symptomatic cardiomyopathy were compared with 27 males with alcohol use disorder with normal cardiac function, the DD genotype was much more common in the males with cardiomyopathy (57 versus 7 percent) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         The prevalence of most variants of well-characterized genes known to cause dilated cardiomyopathy were similar in patients with dilated versus alcohol-induced cardiomyopathy. However, in patients with excess alcohol consumption, patients with truncations of the large structural protein, titin, showed an 8.7 percent absolute decrease in LVEF versus patients without titin truncations [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Although it was once thought that alcohol caused cardiomyopathy primarily through nutritional deficiencies, it is now clear that malnutrition is not a leading factor [
         <a href="#rid17">
          17,18
         </a>
         ]. Even though beriberi heart disease has been classified as an alcohol-induced heart disease, it is distinct from alcohol-induced cardiomyopathy. (See
         <a class="local">
          'Beriberi'
         </a>
         below.)
        </p>
        <p>
         In addition to the above toxicities attributed to ethanol and its metabolites, additives to an alcoholic beverage (for example, cobalt added to beer) may exert a toxic effect on the myocardium. (See
         <a class="medical medical_review" href="/z/d/html/3516.html" rel="external">
          "Causes of dilated cardiomyopathy", section on 'Alcohol'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          PATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The gross and microscopic findings in alcohol-induced cardiomyopathy are generally nonspecific and indistinguishable to those observed in idiopathic dilated cardiomyopathy, though the latter condition may be associated with more marked histologic abnormalities [
         <a href="#rid34">
          34-37
         </a>
         ]. Findings include interstitial fibrosis, myocyte hypertrophy, and myocytolysis [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         However, certain ultrastructural details may be suggestive of alcohol-induced cardiomyopathy. Alcohol, even in small amounts, may result in alterations of mitochondrial structure and function, and endomyocardial biopsy material from patients with chronic alcohol use disorder exhibits structural alterations of the mitochondrial reticulum [
         <a href="#rid39">
          39
         </a>
         ]. In vitro animal studies show the cardiac ultrastructural changes after exposure to ethanol to be consistent and predictable [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
         The progression of gradually developing structural changes is related to the stage of the disease [
         <a href="#rid39">
          39
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The early stage is characterized by spatial reorganization of the mitochondrial reticulum; junctions between mitochondria disappear and the mitochondria form separate clusters, uniformly distributed within a myocyte.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the second and third stages, destructive irreversible changes in the ultrastructural organization of mitochondria develop. Megamitochondria and septate mitochondria appear. A third compartment, containing granules, forms in mitochondria. Many lipofuscin granules appear due to the accumulation of lipids in mitochondria. Structural changes in the mitochondrial reticulum are considered a compensatory adaptation in response to altered myocardial function in alcohol-induced cardiomyopathy.
        </p>
        <p>
        </p>
        <p>
         Changes in enzymatic activity in the myocardium have also been observed in both early and established alcohol-induced cardiomyopathy in humans and animal models. A decrease in the activity of the majority of oxidation-reduction mitochondrial enzymes, normal or increased activity of malate dehydrogenase, increased fatty acid uptake, and increased activity of lysosomal and microsomal enzymes are seen [
         <a href="#rid42">
          42
         </a>
         ]. However, these alterations in activity are nearly identical to those seen in patients with idiopathic dilated cardiomyopathy [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The patient with alcohol-induced cardiomyopathy presents with symptoms and signs like those in patients with other forms of cardiomyopathy. In addition, symptoms and signs of unhealthy alcohol use may be observed. (See
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3509.html" rel="external">
          "Management and prognosis of asymptomatic left ventricular systolic dysfunction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7809.html" rel="external">
          "Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Symptoms and signs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms may develop insidiously, although, in some patients, symptoms of left-sided HF may be acute in onset. Dyspnea, orthopnea, and paroxysmal nocturnal disease are frequently observed. Angina pectoris is suggestive of concomitant coronary artery disease (CAD; or aortic stenosis), though up to one-third of patients with nonischemic cardiomyopathy have chest pain that may resemble angina or be atypical. Palpitation and syncope due to tachyarrhythmias, usually supraventricular, are occasionally present. (See
         <a class="local">
          'Arrhythmias'
         </a>
         below.)
        </p>
        <p>
         Physical examination usually reveals signs of left and right HF including a narrow pulse pressure, often with an elevated diastolic systemic arterial pressure secondary to excessive peripheral vasoconstriction. Cardiomegaly (manifest as a laterally displaced and enlarged apical impulse), protodiastolic (S3), and presystolic (S4) gallop sounds are common. An apical systolic murmur of secondary mitral regurgitation is often found. The severity of right HF varies, but jugular venous distention, ascites, and peripheral edema are common in advanced disease. (See
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults", section on 'Physical examination'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1078.html" rel="external">
          "Auscultation of cardiac murmurs in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1079.html" rel="external">
          "Auscultation of heart sounds"
         </a>
         .)
        </p>
        <p>
         Measurement of the jugular venous pressure may be an important distinguishing feature in determining whether ascites is due to alcohol-induced cardiomyopathy or cirrhosis. The jugular venous pressure is typically normal or low-normal in cirrhosis, unless there is tense ascites which, via upward pressure on the diaphragm, can increase the intrathoracic pressure [
         <a href="#rid44">
          44
         </a>
         ]. Thus, in the absence of tense ascites, an elevated jugular venous pressure is highly suggestive of at least a contribution from cardiac dysfunction. On the other hand, a low normal jugular venous pressure makes HF much less likely as the cause of ascites. (See
         <a class="medical medical_review" href="/z/d/html/1076.html" rel="external">
          "Examination of the jugular venous pulse"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6878.html" rel="external">
          "Clinical manifestations and evaluation of edema in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24111505">
         <span class="h2">
          Initial test results
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine laboratory tests may reveal systemic findings suggestive of alcohol abuse among patients with dilated cardiomyopathy [
         <a href="#rid45">
          45
         </a>
         ]. These include higher values for mean red cell corpuscular volume and hemoglobin, a mild thrombocytopenia, and elevated serum levels of gamma-glutamyl transpeptidase and aspartate aminotransferase (AST). An AST to alanine aminotransferase (ALT) ratio &gt;2 is highly suggestive of alcohol-induced liver disease. (See
         <a class="medical medical_review" href="/z/d/html/3617.html" rel="external">
          "Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis", section on 'Laboratory tests'
         </a>
         .)
        </p>
        <p>
         An electrocardiogram (ECG) is generally performed in patients with suspected alcohol-induced cardiomyopathy, although findings are nonspecific. In patients with alcohol-induced cardiomyopathy, ECG findings may include arrhythmia (particularly atrial fibrillation [AF]), a prolonged corrected QT (QTc) interval, a prolonged QRS duration (which is an adverse prognostic indicator), conduction abnormalities (eg, left bundle branch block or intraventricular conduction delay), and ST and T wave changes [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="local">
          'Arrhythmias'
         </a>
         below and
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p>
         A chest radiograph is not required for diagnosis of cardiomyopathy but is commonly obtained in patients with suspected HF to identify signs of pulmonary edema and to exclude other causes of dyspnea. Some patients with alcohol-induced cardiomyopathy have cardiomegaly (increased cardiothoracic ratio), but this finding has limited specificity and sensitivity for LV dilation compared with echocardiography [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         An echocardiogram is a key test in the diagnosis of alcohol-induced cardiomyopathy, as discussed below. (See
         <a class="local">
          'Echocardiography'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1529549502">
         <span class="h2">
          Arrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with alcohol-induced cardiomyopathy have similar rates of atrial and ventricular arrhythmias to patients with idiopathic dilated cardiomyopathy. The most common manifestation is paroxysmal atrial arrhythmias, especially AF, but ventricular arrhythmias may also occur [
         <a href="#rid48">
          48-51
         </a>
         ]. In a study comparing 94 patients with alcohol-induced cardiomyopathy with 188 patients with idiopathic dilated cardiomyopathy, AF was common in both groups (34 and 24 percent, respectively) [
         <a href="#rid52">
          52
         </a>
         ]. Mild prolongation of the QTc interval on the surface ECG (QTc), a risk factor for ventricular arrhythmias, is found in a proportion of patients with alcohol use disorder compared with persons without alcohol use disorder [
         <a href="#rid53">
          53
         </a>
         ]. Hypomagnesemia and hypokalemia, which occur with increased frequency in patients with alcohol use disorder, may be contributing factors [
         <a href="#rid54">
          54-56
         </a>
         ]. Abstinence appears to reduce the frequency of arrhythmic events  (
         <a class="graphic graphic_figure graphicRef69005" href="/z/d/graphic/69005.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H24111391">
         <span class="h2">
          When to suspect the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of alcohol-induced cardiomyopathy should be suspected in individuals with a history of heavy and prolonged alcohol use with signs of LV dilation (eg, laterally displaced and enlarged apical impulse) or symptoms or signs of HF (eg, dyspnea, fatigue). (See
         <a class="local">
          'Symptoms and signs'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1023366716">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alcohol-induced cardiomyopathy is diagnosed in patients with all three of the following criteria:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term heavy alcohol consumption
         </strong>
         (commonly defined as &gt;80 g per day over a period of at least five years).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Features of dilated cardiomyopathy
         </strong>
         – The following two features are generally identified by echocardiography. If the echocardiogram is suboptimal, cardiovascular magnetic resonance (CMR) or computed tomography (CT) are alternative methods for identifying these features. (See
         <a class="local">
          'Echocardiography'
         </a>
         below and
         <a class="local">
          'Other cardiac imaging'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          LV dilation
         </strong>
         defined as LV end-diastolic volume or LV diastolic dimension (LVDD) greater than 2 standard deviations above normal (by echocardiography, an LVDD &gt;58.4 mm in males and &gt;52.2 mm in females [
         <a href="#rid57">
          57
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          with
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          LVEF below normal
         </strong>
         – While the normal range for LVEF varies among imaging modalities and populations, an LVEF &lt;50 percent is abnormal across modalities and is an accepted threshold for dilated cardiomyopathy [
         <a href="#rid58">
          58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5331.html" rel="external">
          "Tests to evaluate left ventricular systolic function"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          and
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Absence of
         </strong>
         hypertensive, valvular, and ischemic heart disease
         <strong>
          and other causes of dilated cardiomyopathy
         </strong>
         sufficient to have caused the LV systolic dysfunction. CAD should be excluded. (See
         <a class="medical medical_review" href="/z/d/html/3516.html" rel="external">
          "Causes of dilated cardiomyopathy"
         </a>
         and
         <a class="local">
          'Evaluation for CAD'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1005407513">
         <span class="h2">
          Diagnostic tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with suspected alcohol-induced cardiomyopathy should undergo echocardiography as well as evaluation for CAD.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Echocardiography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echocardiography is generally a key diagnostic test in patients with alcohol-induced cardiomyopathy. Alcohol-induced cardiomyopathy is characterized by pronounced LV or biventricular dilation, increased LV mass, thin (or normal thickness) LV walls, diastolic dysfunction, and systolic impairment [
         <a href="#rid10">
          10,58-60
         </a>
         ]. If LV size and systolic function cannot be adequately assessed, other noninvasive cardiac imaging is recommended. (See
         <a class="local">
          'Other cardiac imaging'
         </a>
         below.)
        </p>
        <p>
         Approximately one-half of asymptomatic subjects with alcohol use disorder have a mild increase in LV wall thickness without echocardiographic evidence of decreased myocardial contractility [
         <a href="#rid61">
          61,62
         </a>
         ]. Compared with normal control subjects, persons with alcohol use disorder in one series had increases in the thickness of the LV wall (10.4 versus 8.8 mm) and interventricular septum (11.7 versus 9.6 mm) and in LV mass (145 versus 101 g/m2) [
         <a href="#rid62">
          62
         </a>
         ]. These abnormalities were present despite normal echocardiographic indices of myocardial contractility including ejection fraction, wall excursion, velocity, and circumferential fiber shortening. Systolic time intervals have revealed shortening of ejection time and prolongation of the preejection period.
        </p>
        <p>
         In the 20-year analysis of 2368 healthy subjects from the Coronary Artery Risk Development in Young Adults (CARDIA) registry, chronic alcohol consumption was found to be an independent risk factor for increased indexed LV mass and end-diastolic volume regardless of sex [
         <a href="#rid63">
          63
         </a>
         ]. Despite these changes, no reduction in LVEF was noted. In an echocardiographic study of 89 asymptomatic patients with alcohol use disorder and 30 healthy subjects, LV dilation was the initial manifestation of alcohol-induced cardiomyopathy [
         <a href="#rid10">
          10
         </a>
         ]. LV dilation was followed by an increase in the LV myocardial mass, posterior wall thickness, and diastolic interventricular wall thickness.
        </p>
        <p>
         Mild cardiac dysfunction is frequently detectable in patients with chronic alcohol use disorder before a reduced ejection fraction becomes clinically manifest [
         <a href="#rid10">
          10,64,65
         </a>
         ]. Diastolic dysfunction usually precedes systolic dysfunction and occurs more frequently once systolic impairment becomes apparent [
         <a href="#rid66">
          66
         </a>
         ]. In one study, the extent of diastolic dysfunction was related to the duration of heavy drinking, being most apparent in those with a duration of alcohol use disorder of more than 16 years [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         In another series utilizing two-dimensional speckle tracking echocardiography involving 122 subjects, those who consumed moderate (&gt;90 to 150 mg ethanol daily, three to five days per week for 9 to 20 years) and heavy (&gt;150 mg ethanol daily, six to seven days per week for more than 10 years) alcohol displayed lower circumferential, longitudinal, and radial strain values (systolic) as well as early to late (E/A) filling ratios (diastolic) compared with mild drinkers (&gt;90 mg ethanol daily, three to five days per week for five to eight years) and nondrinkers. These changes show that moderate to heavy alcohol intake can cause subclinical depression of both systolic and diastolic function, and suggest that this echocardiographic technique may be useful in identifying drinkers with asymptomatic LV dysfunction who are at risk of developing alcohol-induced cardiomyopathy [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9767640">
         <span class="h3">
          Evaluation for CAD
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest evaluation for CAD in patients with new HF and/or dilated cardiomyopathy who are potential candidates for revascularization. Noninvasive stress testing is a reasonable first step, since this also provides information for risk stratification and prognosis. However, coronary angiography is an alternative to stress testing in high-risk patients who are potential candidates for revascularization (and is also indicated in patients with intermediate- or high-risk features on stress testing and LV dysfunction). Noninvasive coronary angiography using CMR or CT is a potential option to evaluate CAD in patients with dilated cardiomyopathy of uncertain cause. (See
         <a class="medical medical_review" href="/z/d/html/1548.html" rel="external">
          "Prognostic features of stress testing in patients with known or suspected coronary disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5314.html" rel="external">
          "Clinical utility of cardiovascular magnetic resonance imaging", section on 'Cardiomyopathy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4101582880">
         <span class="h2">
          Additional tests in selected patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional testing is indicated in selected patients with a nondiagnostic echocardiogram or indications for endocardial biopsy to exclude another cause of dilated cardiomyopathy.
        </p>
        <p class="headingAnchor" id="H2720456026">
         <span class="h3">
          Other cardiac imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         If echocardiographic images are suboptimal for identification of features of dilated cardiomyopathy, other cardiac imaging to evaluate ventricular chamber sizes, wall thicknesses, and systolic function is suggested. CMR often provides superior image quality and definition compared with echocardiography, although there are no distinctive CMR features to differentiate alcohol- induced cardiomyopathy from other types of cardiomyopathy [
         <a href="#rid68">
          68
         </a>
         ]. An additional benefit of CMR is its utility in identifying characteristics suggestive of other specific causes of HF and cardiomyopathy, such as ischemic heart disease, amyloidosis, and iron overload. CT is another alternative to echocardiography that can combine coronary artery and ventricular imaging. The use of other cardiac imaging to assess LV size and function (such as radionuclide ventriculography) is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5331.html" rel="external">
          "Tests to evaluate left ventricular systolic function"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9767668">
         <span class="h3">
          Endomyocardial biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endomyocardial biopsy is not generally indicated when the diagnosis of alcohol-induced cardiomyopathy is strongly suspected, since histologic changes in alcohol-induced cardiomyopathy are similar to those seen in idiopathic dilated cardiomyopathy. However, endomyocardial biopsy is indicated in selected cases when other diagnoses (eg, amyloidosis) are suspected based upon the noninvasive evaluation and other means of confirming the diagnosis are unavailable. (See
         <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">
          "Determining the etiology and severity of heart failure or cardiomyopathy"
         </a>
         and
         <a class="local">
          'Differential diagnosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4923.html" rel="external">
          "Endomyocardial biopsy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24113838">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of alcohol-induced cardiomyopathy includes other causes of HF such as hypertensive, valvular, and ischemic heart disease and other inherited and systemic causes of dilated cardiomyopathy, including cirrhotic cardiomyopathy and beriberi; CAD should be excluded, as described above. (See
         <a class="local">
          'Evaluation for CAD'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4034138258">
         <span class="h2">
          Other causes of dilated cardiomyopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis includes other causes of dilated cardiomyopathy  (
         <a class="graphic graphic_table graphicRef74268" href="/z/d/graphic/74268.html" rel="external">
          table 1
         </a>
         ) which should be considered based upon history, symptoms, and signs suggestive of specific etiologies. As an example, ischemic heart disease should generally be excluded in patients with new HF and/or dilated cardiomyopathy. The importance of considering other potential causes was highlighted by a series that included seven patients with alcohol use disorder; endomyocardial biopsy revealed hemochromatosis in two, amyloidosis in one, doxorubicin-related toxicity in one, and evidence of alcohol-induced heart disease in three [
         <a href="#rid69">
          69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3516.html" rel="external">
          "Causes of dilated cardiomyopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">
          "Determining the etiology and severity of heart failure or cardiomyopathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24113880">
         <span class="h2">
          Cirrhotic cardiomyopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis includes cirrhotic cardiomyopathy, another type of myocardial dysfunction that occurs in patients with cirrhosis. Experimental and observational studies have found that cirrhosis is associated with myocardial dysfunction independent of alcohol exposure. The definition, causes, and manifestations of cirrhotic cardiomyopathy are not well established. The condition has been defined as an otherwise unexplained chronic cardiac dysfunction in patients with cirrhosis with impaired contractile responsiveness to stress and/or diastolic dysfunction. The clinical and hemodynamic findings may be similar to those of alcohol-induced cardiomyopathy, and some patients with alcohol-induced cardiomyopathy may develop further cardiac dysfunction when due to alcohol-induced cirrhotic liver failure. Unlike alcohol-induced cardiomyopathy, which can improve with alcohol abstinence, the cardiomyopathy of cirrhosis is only improved by restitution of adequate liver function, either because of liver recovery or transplantation [
         <a href="#rid70">
          70-73
         </a>
         ]. Electrical abnormalities include QT interval prolongation, electrical and mechanical dyssynchrony, and chronotropic incompetence [
         <a href="#rid72">
          72
         </a>
         ]. Most patients with this condition are diagnosed during clinical decompensation of cirrhosis with HF with preserved ejection fraction and/or high-output HF. (See
         <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">
          "Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Cirrhotic cardiomyopathy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">
          "Definition and classification of the cardiomyopathies", section on 'Cirrhotic cardiomyopathy'
         </a>
         .)
        </p>
        <p>
         A careful history and echocardiography (or other noninvasive cardiac imaging) may be helpful in distinguishing cirrhotic cardiomyopathy from alcohol-induced cardiomyopathy and other types of dilated cardiomyopathy. In cirrhotic cardiomyopathy, findings similar to alcohol-induced cardiomyopathy may include a dilated left atrium, thickened LV walls, and systolic and/or diastolic dysfunction [
         <a href="#rid73">
          73
         </a>
         ]. Alcohol-induced cardiomyopathy is generally associated with LV dilation, which may or may not be present in patients with cirrhotic cardiomyopathy.
        </p>
        <p class="headingAnchor" id="H24113988">
         <span class="h2">
          Other causes of atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         While AF is common in patients with alcohol-induced cardiomyopathy, AF also commonly occurs in individuals who consume alcohol who do not have evidence of structural heart disease. AF occurs in up to 60 percent of binge drinkers with or without evidence of underlying myocardial disease, and an increased risk of AF has been reported among males with chronic heavy alcohol consumption [
         <a href="#rid49">
          49,51,74
         </a>
         ]. Most of the cases related to binge drinking occur over weekends or holidays, producing what has been termed "the holiday heart syndrome." (See
         <a class="medical medical_review" href="/z/d/html/1004.html" rel="external">
          "Epidemiology, risk factors, and prevention of atrial fibrillation", section on 'Alcohol'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4002978012">
         <span class="h2">
          Beriberi
         </span>
         <span class="headingEndMark">
          —
         </span>
         Beriberi is a cause of high-output HF caused by severe
         <a class="drug drug_general" data-topicid="9988" href="/z/d/drug information/9988.html" rel="external">
          thiamine
         </a>
         (vitamin B1) deficiency. In contrast to alcohol-induced cardiomyopathy, beriberi heart disease manifests predominantly as right-sided HF, is associated with increased cardiac output (high output failure), and is rapidly reversible after thiamine therapy. (See
         <a class="medical medical_review" href="/z/d/html/3462.html" rel="external">
          "Causes and pathophysiology of high-output heart failure", section on 'Beriberi'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113041.html" rel="external">
          "Clinical manifestations, diagnosis, and management of high-output heart failure"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H415914559">
         <span class="h2">
          General measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should receive a balanced diet and any nutritional deficiencies should be corrected. Supplementation with
         <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">
          vitamin B12
         </a>
         ,
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          vitamin B6
         </a>
         , and folate are important adjuncts, particularly for individuals with sustained heavy alcohol use. Electrolyte disturbances, including hypokalemia and hypomagnesemia, should be monitored and corrected. (See
         <a class="medical medical_review" href="/z/d/html/14614.html" rel="external">
          "Nutritional status in patients with sustained heavy alcohol use"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3598.html" rel="external">
          "Nutritional issues in adult patients with cirrhosis"
         </a>
         .)
        </p>
        <p>
         Patients with alcohol-induced cardiomyopathy often have comorbidities such as depression, liver disease, drug abuse, smoking, and pulmonary disease [
         <a href="#rid4">
          4
         </a>
         ], which need to be addressed concurrently through a multidisciplinary approach. Management of alcohol use disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">
          "Alcohol use disorder: Treatment overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7810.html" rel="external">
          "Alcohol use disorder: Psychosocial management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H352291968">
         <span class="h2">
          Abstinence from alcohol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with alcohol-induced cardiomyopathy require
         <strong>
          total and perpetual abstinence
         </strong>
         from alcohol consumption. (See
         <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">
          "Alcohol use disorder: Treatment overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7810.html" rel="external">
          "Alcohol use disorder: Psychosocial management"
         </a>
         .)
        </p>
        <p>
         Small observational studies have suggested that LV function improves in some patients with abstinence [
         <a href="#rid48">
          48,75-82
         </a>
         ]. Short duration of HF symptoms prior to abstinence may favor recovery [
         <a href="#rid77">
          77
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/7810.html" rel="external">
          "Alcohol use disorder: Psychosocial management"
         </a>
         ). No marker for reversibility has been identified. Though some studies have cited lack of myocardial interstitial fibrosis as a potential indicator of reversibility, limited data on morphometry have yielded mixed results [
         <a href="#rid34">
          34,83
         </a>
         ].
        </p>
        <p>
         The potential efficacy of abstinence is illustrated by the following studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 101 patients with alcohol-induced cardiomyopathy who were followed for a median period of 82 months, 42 percent of patients recovered (defined by an increase in LVEF of ≥10 percent to a final value of ≥40 percent). None of the patients who continued to drink heavily recovered. There was no difference in the recovery rate between abstainers (44 percent) and those who reduced drinking to moderate (45 percent). The independent predictors for LVEF recovery were the use of beta blocker therapy, narrow QRS complex (&lt;120 ms), and the absence of diuretics use [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another series of 14 patients with alcohol-induced cardiomyopathy and severe HF, nine patients were followed for 36 months [
         <a href="#rid81">
          81
         </a>
         ]. LVEF in the nine patients improved significantly at six months (mean of 37 versus 22 percent at baseline) with continued improvement at 36 months (mean of 43 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an echocardiographic study of 13 patients with alcohol-induced cardiomyopathy, five demonstrated normalization of LVEF to 55 percent or more and reduction of LV end-diastolic dimension to 5.7 cm or less after total abstinence for six months [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         If abstinence cannot be achieved, we counsel the patient to reduce their alcohol consumption as much as possible. Studies have shown that improvement in LVEF can occur with "controlled" alcohol consumption (ie, 20 to 60 g per day).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective study of 55 males with a cardiomyopathy who consumed ≥100 g alcohol per day for at least 10 years  (
         <a class="graphic graphic_figure graphicRef134858" href="/z/d/graphic/134858.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid84">
          84
         </a>
         ], the improvement in LVEF at one year was similar in abstainers and those who controlled their intake (20 to 60 g per day). By contrast, patients who continued to drink &gt;80 g per day had a further deterioration in LVEF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly, a study of 94 patients with alcohol-induced cardiomyopathy found that those who reduced their alcohol intake to moderate levels (&lt;80 g per day; most &lt;20 to 30 g per day) exhibited similar survival and improvement in LVEF as those who abstained from alcohol [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H352292014">
         <span class="h2">
          Pharmacologic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of HF with reduced ejection fraction generally includes a combination of a diuretic, beta blocker, angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor-neprilysin inhibitor or angiotensin II receptor blocker, a mineralocorticoid receptor antagonist, and an sodium-glucose co-transporter 2 inhibitor as indicated. (See
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults"
         </a>
         .)
        </p>
        <p>
         In patients with asymptomatic LV systolic dysfunction with LVEF ≤40 percent, pharmacotherapy coupled with abstinence may halt or reverse the negative remodeling of the myocardium (see
         <a class="medical medical_review" href="/z/d/html/3509.html" rel="external">
          "Management and prognosis of asymptomatic left ventricular systolic dysfunction"
         </a>
         ). With abstinence and/or pharmacologic therapy, an increase in LVEF to &gt;40 percent has a good prognosis with very low mortality [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         In a case control study of patients with alcohol-induced cardiomyopathy (n = 60), the use of either
         <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">
          carvedilol
         </a>
         (6.25 to 12.5 mg twice daily) or trimetazidine (20 mg three times daily) with conventional HF drugs for 12 weeks was associated with higher LVEF and lower C-reactive protein, as well as longer walking distance in six minutes [
         <a href="#rid85">
          85
         </a>
         ]. The conventional drugs used included ACE inhibitors,
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         , diuretics, and
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         . The heart rate, blood pressure, cardiothoracic ratio, and LV internal diameter were lower with either carvedilol or trimetazidine than the control group. While these benefits were expected with carvedilol, the use of trimetazidine was novel.
        </p>
        <p class="headingAnchor" id="H3207896075">
         <span class="h2">
          Management of arrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Arrhythmias are treated according to standard recommendations. (See
         <a class="medical medical_review" href="/z/d/html/968.html" rel="external">
          "Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/977.html" rel="external">
          "The management of atrial fibrillation in patients with heart failure"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who abstain from alcohol or moderate alcohol use have a prognosis better than or similar to that seen with idiopathic dilated cardiomyopathy, while continued heavy alcohol is associated with a worse prognosis.
        </p>
        <p>
         Some studies have found similar mortality rates in patients with alcohol-induced cardiomyopathy who stop drinking as in patients with idiopathic cardiomyopathy and worse outcomes in patients with alcohol-induced cardiomyopathy who continue to drink. As an example, a study of 50 patients with alcohol-induced cardiomyopathy found that the cardiac death rate at four-year follow-up for those who stopped drinking was the same as that for 84 patients with an idiopathic dilated cardiomyopathy; however, mortality was higher for those with alcohol-induced cardiomyopathy who continued to drink  (
         <a class="graphic graphic_figure graphicRef79337" href="/z/d/graphic/79337.html" rel="external">
          figure 4
         </a>
         ) [
         <a href="#rid14">
          14
         </a>
         ]. In another study of 338 males with a dilated cardiomyopathy, 23 percent had an alcohol-induced cardiomyopathy; those who continued to drink had a lower seven-year transplant-free survival compared with those who stopped drinking or those with an idiopathic cardiomyopathy (27 versus 45 and 53 percent) [
         <a href="#rid86">
          86
         </a>
         ]. One review estimated the four-year mortality of alcohol-induced cardiomyopathy patients who continued to drink as 50 percent [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
         In one study, alcohol-induced cardiomyopathy was the underlying cause of sudden cardiac death in five percent of cases [
         <a href="#rid88">
          88
         </a>
         ]. Of the patients with autopsy-proven alcohol-induced cardiomyopathy, only 22 percent had a cardiac diagnosis made prior to death, which suggests that the true prevalence of alcohol-induced cardiomyopathy was underestimated.
        </p>
        <p>
         By contrast, other studies have found that the rate of progression and mortality in patients with alcohol-induced cardiomyopathy was significantly lower than seen in idiopathic cardiomyopathy [
         <a href="#rid86">
          86,89
         </a>
         ]. The largest series of patients with alcohol-induced cardiomyopathy, and the earliest to include significant numbers of patients receiving beta blocker therapy as well as angiotensin-converting enzyme inhibitor (or angiotensin II receptor blocker) therapy, reported a better prognosis with alcohol-induced cardiomyopathy than with idiopathic dilated cardiomyopathy [
         <a href="#rid52">
          52
         </a>
         ]. Transplant-free survival at median 59 months follow-up was significantly higher among the 94 patients with alcohol-induced cardiomyopathy compared with the 188 patients with dilated cardiomyopathy (67 versus 52 percent). During follow-up of patients with alcohol-induced cardiomyopathy, 63 percent reported abstinence, 32 percent had reduced intake to &lt;80 g per day, and 5 percent consumed &gt;80 g per day of alcohol.
        </p>
        <p>
         Among patients with alcohol-induced cardiomyopathy, independent predictors of death or heart transplantation included AF, QRS duration &gt;120 ms, and lack of beta blocker therapy. Of note, transplant-free survival was similar among abstainers and those who reduced alcohol intake to &lt;80 g per day (most &lt;20 to 30 g per day).
        </p>
        <p>
         In-hospital mortality of alcohol-induced cardiomyopathy patients is around 4.5 percent; half of admissions are due to cardiac etiology, with a quarter due to acute HF [
         <a href="#rid4">
          4
         </a>
         ]. Patients with alcohol-induced cardiomyopathy frequently have comorbidities that adversely influence prognosis such as depression, liver disease, drug abuse, hypertension, diabetes, smoking, and pulmonary disease.
        </p>
        <p class="headingAnchor" id="H3170660166">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">
          "Society guideline links: Heart failure in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21932325">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcohol-induced cardiomyopathy is diagnosed in patients with all three of the following criteria: long-term heavy alcohol consumption (commonly defined as &gt;80 g per day over a period of at least five years), features of dilated cardiomyopathy (left ventricular [LV] dilation and reduced LV ejection fraction [LVEF]), and absence of other causes of dilated cardiomyopathy. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The relationship between alcohol consumption and heart failure (HF) appears to be J-shaped, with reduced risk at low to moderate levels of alcohol consumption (ie, up to one drink per day for females and up to two drinks per day for males) but increased risk at higher levels of alcohol intake. (See
         <a class="local">
          'Relation to alcohol consumption'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The pathogenesis of alcohol-induced cardiomyopathy is not well understood, but experimental data have suggested that ethanol consumption may directly or indirectly (via metabolites) cause oxidative stress, apoptosis, impaired mitochondrial bioenergetics, altered fatty acid metabolism, and increase myocardial protein catabolism. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient with alcohol-induced cardiomyopathy presents with symptoms and signs like those in patients with HF, asymptomatic LV systolic dysfunction, or dilated cardiomyopathy of any etiology. In addition, symptoms and signs of unhealthy alcohol use may be observed. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The differential diagnosis of alcohol-induced cardiomyopathy includes other causes of HF, such as hypertensive, valvular, and ischemic heart disease and other inherited and systemic causes of dilated cardiomyopathy. CAD should be excluded. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above and
         <a class="local">
          'Evaluation for CAD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with alcohol-induced cardiomyopathy require
         <strong>
          total and perpetual abstinence
         </strong>
         from alcohol consumption. If abstinence cannot be achieved, we counsel the patient to reduce their alcohol consumption as much as possible. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who abstain from alcohol or moderate alcohol use have a prognosis better than or similar to that seen with idiopathic dilated cardiomyopathy, while continued heavy alcohol use is associated with a worse prognosis. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           McKenna CJ, Codd MB, McCann HA, Sugrue DD. Alcohol consumption and idiopathic dilated cardiomyopathy: a case control study. Am Heart J 1998; 135:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piano MR, Schwertz DW. Alcoholic heart disease: a review. Heart Lung 1994; 23:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guzzo-Merello G, Cobo-Marcos M, Gallego-Delgado M, Garcia-Pavia P. Alcoholic cardiomyopathy. World J Cardiol 2014; 6:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ram P, Lo KB, Shah M, et al. National trends in hospitalizations and outcomes in patients with alcoholic cardiomyopathy. Clin Cardiol 2018; 41:1423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urbano-Márquez A, Estruch R, Fernández-Solá J, et al. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA 1995; 274:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Solà J, Estruch R, Nicolás JM, et al. Comparison of alcoholic cardiomyopathy in women versus men. Am J Cardiol 1997; 80:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baraona E, Abittan CS, Dohmen K, et al. Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res 2001; 25:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilke A, Kaiser A, Ferency I, Maisch B. [Alcohol and myocarditis]. Herz 1996; 21:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee WK, Regan TJ. Alcoholic cardiomyopathy: is it dose-dependent? Congest Heart Fail 2002; 8:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarević AM, Nakatani S, Nesković AN, et al. Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking. J Am Coll Cardiol 2000; 35:1599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kajander OA, Kupari M, Laippala P, et al. Dose dependent but non-linear effects of alcohol on the left and right ventricle. Heart 2001; 86:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelbaek H, Gjørup T, Brynjolf I, et al. Acute effects of alcohol on left ventricular function in healthy subjects at rest and during upright exercise. Am J Cardiol 1985; 55:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waszkiewicz N, Szulc A, Zwierz K. Binge drinking-induced subtle myocardial injury. Alcohol Clin Exp Res 2013; 37:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fauchier L, Babuty D, Poret P, et al. Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy. Eur Heart J 2000; 21:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kupari M, Koskinen P, Suokas A, Ventilä M. Left ventricular filling impairment in asymptomatic chronic alcoholics. Am J Cardiol 1990; 66:1473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Estruch R, Fernández-Solá J, Sacanella E, et al. Relationship between cardiomyopathy and liver disease in chronic alcoholism. Hepatology 1995; 22:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel VB, Why HJ, Richardson PJ, Preedy VR. The effects of alcohol on the heart. Adverse Drug React Toxicol Rev 1997; 16:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lange LG, Sobel BE. Myocardial metabolites of ethanol. Circ Res 1983; 52:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preedy VR, Atkinson LM, Richardson PJ, Peters TJ. Mechanisms of ethanol-induced cardiac damage. Br Heart J 1993; 69:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang X, Li SY, Brown RA, Ren J. Ethanol and acetaldehyde in alcoholic cardiomyopathy: from bad to ugly en route to oxidative stress. Alcohol 2004; 32:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oba T, Maeno Y, Ishida K. Differential contribution of clinical amounts of acetaldehyde to skeletal and cardiac muscle dysfunction in alcoholic myopathy. Curr Pharm Des 2005; 11:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ren J, Wold LE. Mechanisms of alcoholic heart disease. Ther Adv Cardiovasc Dis 2008; 2:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laurent D, Mathew JE, Mitry M, et al. Chronic ethanol consumption increases myocardial mitochondrial DNA mutations: a potential contribution by mitochondrial topoisomerases. Alcohol Alcohol 2014; 49:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figueredo VM, Chang KC, Baker AJ, Camacho SA. Chronic alcohol-induced changes in cardiac contractility are not due to changes in the cytosolic Ca2+ transient. Am J Physiol 1998; 275:H122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas AP, Rozanski DJ, Renard DC, Rubin E. Effects of ethanol on the contractile function of the heart: a review. Alcohol Clin Exp Res 1994; 18:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piano MR, Phillips SA. Alcoholic cardiomyopathy: pathophysiologic insights. Cardiovasc Toxicol 2014; 14:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steiner JL, Lang CH. Etiology of alcoholic cardiomyopathy: Mitochondria, oxidative stress and apoptosis. Int J Biochem Cell Biol 2017; 89:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandt M, Wenzel P. Alcohol puts the heart under pressure: Acetaldehyde activates a localized renin angiotensin aldosterone system within the myocardium in alcoholic cardiomyopathy. Int J Cardiol 2018; 257:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu Z, Huang Y, Lv L, et al. Acute ethanol exposure-induced autophagy-mediated cardiac injury via activation of the ROS-JNK-Bcl-2 pathway. J Cell Physiol 2018; 233:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu B, Zhang R, Wei S, et al. ALDH2 protects against alcoholic cardiomyopathy through a mechanism involving the p38 MAPK/CREB pathway and local renin-angiotensin system inhibition in cardiomyocytes. Int J Cardiol 2018; 257:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leibing E, Meyer T. Enzymes and signal pathways in the pathogenesis of alcoholic cardiomyopathy. Herz 2016; 41:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Solà J, Nicolás JM, Oriola J, et al. Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. Ann Intern Med 2002; 137:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ware JS, Amor-Salamanca A, Tayal U, et al. Genetic Etiology for Alcohol-Induced Cardiac Toxicity. J Am Coll Cardiol 2018; 71:2293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teragaki M, Takeuchi K, Takeda T. Clinical and histologic features of alcohol drinkers with congestive heart failure. Am Heart J 1993; 125:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chun JL, O'Brien R, Berry SE. Cardiac dysfunction and pathology in the dystrophin and utrophin-deficient mouse during development of dilated cardiomyopathy. Neuromuscul Disord 2012; 22:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tandler B, Dunlap M, Hoppel CL, Hassan M. Giant mitochondria in a cardiomyopathic heart. Ultrastruct Pathol 2002; 26:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li X, Nie Y, Lian H, Hu S. Histopathologic features of alcoholic cardiomyopathy compared with idiopathic dilated cardiomyopathy. Medicine (Baltimore) 2018; 97:e12259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez-Sola J, Estruch R, Grau JM, et al. The relation of alcoholic myopathy to cardiomyopathy. Ann Intern Med 1994; 120:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sudarikova YuV, Bakeeva LE, Tsiplenkova VG. Ultrastructure of mitochondrial reticulum of human cardiomyocytes in alcohol cardiomyopathy. Biochemistry (Mosc) 1997; 62:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mashimo K, Sato S, Ohno Y. Chronic effects of ethanol on cultured myocardial cells: ultrastructural and morphometric studies. Virchows Arch 2003; 442:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikami K, Sato S, Watanabe T. Acute effects of ethanol on cultured myocardial cells: an ultrastructural study. Alcohol Alcohol 1990; 25:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu C, Ge F, Hyodo E, et al. Chronic ethanol consumption increases cardiomyocyte fatty acid uptake and decreases ventricular contractile function in C57BL/6J mice. J Mol Cell Cardiol 2013; 59:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherpachenko NM. [Changes in the enzymatic activity in the myocardium of patients with idiopathic and secondary dilated cardiomyopathy]. Arkh Patol 1993; 55:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guazzi M, Polese A, Magrini F, et al. Negative influences of ascites on the cardiac function of cirrhotic patients. Am J Med 1975; 59:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang RY, Alterman AI, Searles JS, McLellan AT. Alcohol abuse in patients with dilated cardiomyopathy. Laboratory vs clinical detection. Arch Intern Med 1990; 150:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang W, Luo R, Tang Y, et al. The Prognostic Factors of Alcoholic Cardiomyopathy: A single-center cohort study. Medicine (Baltimore) 2018; 97:e11744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loomba RS, Shah PH, Nijhawan K, et al. Cardiothoracic ratio for prediction of left ventricular dilation: a systematic review and pooled analysis. Future Cardiol 2015; 11:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Regan TJ. Alcoholic cardiomyopathy. Prog Cardiovasc Dis 1984; 27:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ettinger PO, Wu CF, De La Cruz C Jr, et al. Arrhythmias and the "Holiday Heart": alcohol-associated cardiac rhythm disorders. Am Heart J 1978; 95:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckingham TA, Kennedy HL, Goenjian AK, et al. Cardiac arrhythmias in a population admitted to an acute alcoholic detoxification center. Am Heart J 1985; 110:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frost L, Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med 2004; 164:1993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guzzo-Merello G, Segovia J, Dominguez F, et al. Natural history and prognostic factors in alcoholic cardiomyopathy. JACC Heart Fail 2015; 3:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corović N, Duraković Z, Misigoj-Duraković M. Dispersion of the corrected QT and JT interval in the electrocardiogram of alcoholic patients. Alcohol Clin Exp Res 2006; 30:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fauchier L. Alcoholic cardiomyopathy and ventricular arrhythmias. Chest 2003; 123:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elisaf M, Merkouropoulos M, Tsianos EV, Siamopoulos KC. Pathogenetic mechanisms of hypomagnesemia in alcoholic patients. J Trace Elem Med Biol 1995; 9:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elisaf M, Liberopoulos E, Bairaktari E, Siamopoulos K. Hypokalaemia in alcoholic patients. Drug Alcohol Rev 2002; 21:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozkurt B, Colvin M, Cook J, et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. Circulation 2016; 134:e579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piano MR. Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. Chest 2002; 121:1638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathews EC Jr, Gardin JM, Henry WL, et al. Echocardiographic abnormalities in chronic alcoholics with and without overt congestive heart failure. Am J Cardiol 1981; 47:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orlando E, Gennari P, Boari C. [Echocardiographic study of the left ventricle in chronic alcoholism]. Minerva Med 1980; 71:3235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Askanas A, Udoshi M, Sadjadi SA. The heart in chronic alcoholism: a noninvasive study. Am Heart J 1980; 99:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigues P, Santos-Ribeiro S, Teodoro T, et al. Association Between Alcohol Intake and Cardiac Remodeling. J Am Coll Cardiol 2018; 72:1452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dancy M, Bland JM, Leech G, et al. Preclinical left ventricular abnormalities in alcoholics are independent of nutritional status, cirrhosis, and cigarette smoking. Lancet 1985; 1:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelbaek H, Eriksen J, Brynjolf I, et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol 1984; 54:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Solà J, Nicolás JM, Paré JC, et al. Diastolic function impairment in alcoholics. Alcohol Clin Exp Res 2000; 24:1830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Li G, Sun Y, et al. Left Ventricular Strain and Rotation by 2-D Speckle Tracking Echocardiography Identify Early Alcoholic Cardiomyopathy. Ultrasound Med Biol 2016; 42:1741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francone M. Role of cardiac magnetic resonance in the evaluation of dilated cardiomyopathy: diagnostic contribution and prognostic significance. ISRN Radiol 2014; 2014:365404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ocel JJ, Edwards WD, Tazelaar HD, et al. Heart and liver disease in 32 patients undergoing biopsy of both organs, with implications for heart or liver transplantation. Mayo Clin Proc 2004; 79:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milani A, Zaccaria R, Bombardieri G, et al. Cirrhotic cardiomyopathy. Dig Liver Dis 2007; 39:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Møller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010; 53:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zardi EM, Abbate A, Zardi DM, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010; 56:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timoh T, Protano MA, Wagman G, et al. A perspective on cirrhotic cardiomyopathy. Transplant Proc 2011; 43:1649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mukamal KJ, Tolstrup JS, Friberg J, et al. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation 2005; 112:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renault A, Mansourati J, Genet L, Blanc JJ. [Dilated cardiomyopathies in severe cardiac failure in chronic alcoholics: clinical course after complete withdrawal]. Rev Med Interne 1993; 14:942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nethala V, Brown EJ Jr, Timson CR, Patcha R. Reversal of alcoholic cardiomyopathy in a patient with severe coronary artery disease. Chest 1993; 104:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demakis JG, Proskey A, Rahimtoola SH, et al. The natural course of alcoholic cardiomyopathy. Ann Intern Med 1974; 80:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mansourati J, Forneiro I, Genet L, et al. [Regression of dilated cardiomyopathy in a chronic alcoholic patient after abstinence from alcohol]. Arch Mal Coeur Vaiss 1990; 83:1849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agatston AS, Snow ME, Samet P. Regression of severe alcoholic cardiomyopathy after abstinence of 10 weeks. Alcohol Clin Exp Res 1986; 10:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masani F, Kato H, Sasagawa Y, et al. [An echocardiographic study of alcoholic cardiomyopathy after total abstinence]. J Cardiol 1990; 20:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillo P, Mansourati J, Maheu B, et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol 1997; 79:1276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amor-Salamanca A, Guzzo-Merello G, González-López E, et al. Prognostic Impact and Predictors of Ejection Fraction Recovery in Patients With Alcoholic Cardiomyopathy. Rev Esp Cardiol (Engl Ed) 2018; 71:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Vecchia LL, Bedogni F, Bozzola L, et al. Prediction of recovery after abstinence in alcoholic cardiomyopathy: role of hemodynamic and morphometric parameters. Clin Cardiol 1996; 19:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolás JM, Fernández-Solà J, Estruch R, et al. The effect of controlled drinking in alcoholic cardiomyopathy. Ann Intern Med 2002; 136:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li H, Liu FY, Li XL, et al. Clinical effects of carvedilol and trimetazidine for the treatmentof alcoholic myocardiopathy. Exp Ther Med 2016; 12:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gavazzi A, De Maria R, Parolini M, Porcu M. Alcohol abuse and dilated cardiomyopathy in men. Am J Cardiol 2000; 85:1114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skotzko CE, Vrinceanu A, Krueger L, Freudenberger R. Alcohol use and congestive heart failure: incidence, importance, and approaches to improved history taking. Heart Fail Rev 2009; 14:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hietanen S, Herajärvi J, Junttila J, et al. Characteristics of subjects with alcoholic cardiomyopathy and sudden cardiac death. Heart 2020; 106:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prazak P, Pfisterer M, Osswald S, et al. Differences of disease progression in congestive heart failure due to alcoholic as compared to idiopathic dilated cardiomyopathy. Eur Heart J 1996; 17:251.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3467 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9588413" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Alcohol consumption and idiopathic dilated cardiomyopathy: a case control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8150642" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Alcoholic heart disease: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25228956" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Alcoholic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30178565" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : National trends in hospitalizations and outcomes in patients with alcoholic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7596003" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9285662" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Comparison of alcoholic cardiomyopathy in women versus men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11329488" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Gender differences in pharmacokinetics of alcohol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8805005" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : [Alcohol and myocarditis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12461319" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Alcoholic cardiomyopathy: is it dose-dependent?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10807466" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11559683" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Dose dependent but non-linear effects of alcohol on the left and right ventricle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3966376" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Acute effects of alcohol on left ventricular function in healthy subjects at rest and during upright exercise.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23800345" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Binge drinking-induced subtle myocardial injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10653678" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2251994" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Left ventricular filling impairment in asymptomatic chronic alcoholics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7635421" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Relationship between cardiomyopathy and liver disease in chronic alcoholism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9192055" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The effects of alcohol on the heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6831662" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Myocardial metabolites of ethanol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8461216" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mechanisms of ethanol-induced cardiac damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15282111" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Ethanol and acetaldehyde in alcoholic cardiomyopathy: from bad to ugly en route to oxidative stress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15777233" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Differential contribution of clinical amounts of acetaldehyde to skeletal and cardiac muscle dysfunction in alcoholic myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19124444" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Mechanisms of alcoholic heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24852753" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Chronic ethanol consumption increases myocardial mitochondrial DNA mutations: a potential contribution by mitochondrial topoisomerases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9688904" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Chronic alcohol-induced changes in cardiac contractility are not due to changes in the cytosolic Ca2+ transient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8198208" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Effects of ethanol on the contractile function of the heart: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24671642" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Alcoholic cardiomyopathy: pathophysiologic insights.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28606389" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Etiology of alcoholic cardiomyopathy: Mitochondria, oxidative stress and apoptosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29506696" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Alcohol puts the heart under pressure: Acetaldehyde activates a localized renin angiotensin aldosterone system within the myocardium in alcoholic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28369910" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Acute ethanol exposure-induced autophagy-mediated cardiac injury via activation of the ROS-JNK-Bcl-2 pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29506687" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : ALDH2 protects against alcoholic cardiomyopathy through a mechanism involving the p38 MAPK/CREB pathway and local renin-angiotensin system inhibition in cardiomyocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27418001" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Enzymes and signal pathways in the pathogenesis of alcoholic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12204015" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29773157" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Genetic Etiology for Alcohol-Induced Cardiac Toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8438710" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical and histologic features of alcohol drinkers with congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22266080" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Cardiac dysfunction and pathology in the dystrophin and utrophin-deficient mouse during development of dilated cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12184376" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Giant mitochondria in a cardiomyopathic heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30278496" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Histopathologic features of alcoholic cardiomyopathy compared with idiopathic dilated cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8116990" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The relation of alcoholic myopathy to cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9457763" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Ultrastructure of mitochondrial reticulum of human cardiomyocytes in alcohol cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12715171" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Chronic effects of ethanol on cultured myocardial cells: ultrastructural and morphometric studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2085348" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Acute effects of ethanol on cultured myocardial cells: an ultrastructural study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23422163" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Chronic ethanol consumption increases cardiomyocyte fatty acid uptake and decreases ventricular contractile function in C57BL/6J mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7980067" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : [Changes in the enzymatic activity in the myocardium of patients with idiopathic and secondary dilated cardiomyopathy].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1155476" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Negative influences of ascites on the cardiac function of cirrhotic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1970474" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Alcohol abuse in patients with dilated cardiomyopathy. Laboratory vs clinical detection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30075591" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The Prognostic Factors of Alcoholic Cardiomyopathy: A single-center cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25760876" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Cardiothoracic ratio for prediction of left ventricular dilation: a systematic review and pooled analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6093193" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Alcoholic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/636996" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Arrhythmias and the "Holiday Heart": alcohol-associated cardiac rhythm disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4061271" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cardiac arrhythmias in a population admitted to an acute alcoholic detoxification center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15477433" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Alcohol and risk of atrial fibrillation or flutter: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25458176" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Natural history and prognostic factors in alcoholic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16433743" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Dispersion of the corrected QT and JT interval in the electrocardiogram of alcoholic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12684336" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Alcoholic cardiomyopathy and ventricular arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8808192" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Pathogenetic mechanisms of hypomagnesemia in alcoholic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12189007" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Hypokalaemia in alcoholic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25559473" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27832612" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12006456" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6451168" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Echocardiographic abnormalities in chronic alcoholics with and without overt congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6450342" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : [Echocardiographic study of the left ventricle in chronic alcoholism].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6444262" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The heart in chronic alcoholism: a noninvasive study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30236306" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Association Between Alcohol Intake and Cardiac Remodeling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2860335" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Preclinical left ventricular abnormalities in alcoholics are independent of nutritional status, cirrhosis, and cigarette smoking.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6486037" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11141042" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Diastolic function impairment in alcoholics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27156014" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Left Ventricular Strain and Rotation by 2-D Speckle Tracking Echocardiography Identify Early Alcoholic Cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24967294" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Role of cardiac magnetic resonance in the evaluation of dilated cardiomyopathy: diagnostic contribution and prognostic significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15065614" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Heart and liver disease in 32 patients undergoing biopsy of both organs, with implications for heart or liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17383244" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Cirrhotic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20462649" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Cirrhotic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20688208" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cirrhotic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21693251" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : A perspective on cirrhotic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16157768" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8009044" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : [Dilated cardiomyopathies in severe cardiac failure in chronic alcoholics: clinical course after complete withdrawal].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8339663" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Reversal of alcoholic cardiomyopathy in a patient with severe coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4273902" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The natural course of alcoholic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2125195" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : [Regression of dilated cardiomyopathy in a chronic alcoholic patient after abstinence from alcohol].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3530014" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Regression of severe alcoholic cardiomyopathy after abstinence of 10 weeks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2131353" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : [An echocardiographic study of alcoholic cardiomyopathy after total abstinence].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9164905" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29650446" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Prognostic Impact and Predictors of Ejection Fraction Recovery in Patients With Alcoholic Cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8903537" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Prediction of recovery after abstinence in alcoholic cardiomyopathy: role of hemodynamic and morphometric parameters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11827495" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The effect of controlled drinking in alcoholic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27446307" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Clinical effects of carvedilol and trimetazidine for the treatmentof alcoholic myocardiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10781762" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Alcohol abuse and dilated cardiomyopathy in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18034302" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Alcohol use and congestive heart failure: incidence, importance, and approaches to improved history taking.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31551291" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Characteristics of subjects with alcoholic cardiomyopathy and sudden cardiac death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8732379" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Differences of disease progression in congestive heart failure due to alcoholic as compared to idiopathic dilated cardiomyopathy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
